Abstract:Key PointsHypoxia-inducible factor 1 (HIF-1) is a heterodimeric protein that consists of two proteins — HIF-1α and HIF-1β. HIF-1 activates the transcription of many genes that code for proteins that are involved in angiogenesis, glucose metabolism, cell proliferation/survival and invasion/metastasis.HIF-1α protein synthesis is regulated by activation of the phosphatidylinositol 3-kinase (PI3K) and ERK mitogen-activated protein kinase (MAPK) pathways. These pathways can be activated by signalling via receptor tyrosine kinases, non-receptor tyrosine kinases or G-protein-coupled receptors.HIF-1α protein degradation is regulated by O2-dependent prolyl hydroxylation, which targets the protein for ubiquitylation by E3 ubiquitin-protein ligases. These ligases contain the von Hippel–Lindau tumour-suppressor protein (VHL), which binds specifically to hydroxylated HIF-1α. Ubiquitylated HIF-1α is rapidly degraded by the proteasome.HIF-1α is overexpressed in human cancers as a result of intratumoral hypoxia as well as genetic alterations, such as gain-of-function mutations in oncogenes (for example, ERBB2) and loss-of-function mutations in tumour-suppressor genes (for example, VHL and PTEN). HIF-1α overexpression is associated with treatment failure and increased mortality.In xenograft assays, manipulation of HIF-1 activity by genetic or pharmacological means has marked effects on tumour growth because of effects on angiogenesis, glucose metabolism and/or cell survival.Screens are underway to identify small-molecule inhibitors of HIF-1 and to test their efficacy as anticancer agents. These drugs might represent an important component of novel combination therapies that are designed to target signalling molecules in cancer cells.

HIF-1-Regulated Glucose Metabolism: A Key to Apoptosis Resistance?

HIF-1-Independent Mechanisms Regulating Metabolic Adaptation in Hypoxic Cancer Cells

Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics

HIF-1-Dependent Reprogramming of Glucose Metabolic Pathway of Cancer Cells and Its Therapeutic Significance

HIF-1α pathway: role, regulation and intervention for cancer therapy

Therapeutic Targeting Hypoxia-Inducible Factor (HIF-1) in Cancer: Cutting Gordian Knot of Cancer Cell Metabolism

Survival Pathways of HIF-Deficient Tumour Cells: TCA Inhibition, Peroxisomal Fatty Acid Oxidation Activation and an AMPK-PGC-1α Hypoxia Sensor

Hypoxia-Inducible Factor-Dependent and Independent Mechanisms Underlying Chemoresistance of Hypoxic Cancer Cells

Hypoxia Dictates Metabolic Rewiring of Tumors: Implications for Chemoresistance

Targeting HIF-1 for cancer therapy

Cancer Cell Metabolism in Hypoxia: Role of HIF-1 as Key Regulator and Therapeutic Target

Therapeutic Targeting of Hypoxia-Inducible Factors in Cancer

Central role of hypoxia-inducible factor-1α in metabolic reprogramming of cancer cells: A review

Metabolomic Investigations into Hypoxia-Mediated Metabolic Reprogramming of Pancreatic Cancer Cells

Hypoxia-regulated gene network in drug resistance and cancer progression

The role of hypoxia-inducible factors in metabolic diseases

Regulation of glycolysis by the hypoxia‐inducible factor (HIF): implications for cellular physiology

HIF-1α signaling: Essential roles in tumorigenesis and implications in targeted therapies

How to overcome (and exploit) tumor hypoxia for targeted gene therapy

Regulation of the HIF switch in human endothelial and cancer cells

Metabolic profiling reveals potential metabolic markers associated with Hypoxia Inducible Factor-mediated signalling in hypoxic cancer cells